![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biogen and Alectos Agree Over Parkinson’s Disease Drug Collaboration, Plus Unnamed Molecules
Biogen and Alectos Agree Over Parkinson’s Disease Drug Collaboration, Plus Unnamed Molecules
Biogen and Alectos Therapeutics have inked a licensing and collaboration agreement to develop Alectos’ lead investigational compound, AL01811, for treatment of patients with Parkinson’s disease.
Under the agreement, Biogen will pay $15 million upfront to Alectos for an exclusive global license to AL01811 and additional “unnamed backup molecules.”
Alectos is also eligible to receive $77.5 million in potential development payments and $630 million in potential commercial payments for reaching certain milestones.
Upcoming Events
-
21Oct